{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acquired+Immune+Deficiency+Syndrome&page=3", "query": { "condition": "Acquired Immune Deficiency Syndrome", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1759, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acquired+Immune+Deficiency+Syndrome&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acquired+Immune+Deficiency+Syndrome&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T12:31:16.170Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05406583", "title": "A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life)", "type": "DRUG" }, { "name": "Dolutegravir 5 mg Dispersible Tablets (single doses)", "type": "DRUG" }, { "name": "Dolutegravir 5 mg Dispersible Tablets (chronic dose)", "type": "DRUG" }, { "name": "Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 96, "start_date": "2022-10-05", "completion_date": "2025-05-22", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406583" }, { "nct_id": "NCT00000895", "title": "A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mycobacterium Avium-intracellulare Infection", "HIV Infections" ], "interventions": [ { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": null, "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000895" }, { "nct_id": "NCT03617705", "title": "Alcohol Monitor Validation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "Skyn Monitor Lab Session 1", "type": "DEVICE" }, { "name": "Skyn Monitor Field Test with EMA App", "type": "DEVICE" }, { "name": "Skyn Monitor Lab Session 2", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "21 Years to 64 Years" }, "enrollment_count": 49, "start_date": "2019-04-01", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 2, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03617705" }, { "nct_id": "NCT00000829", "title": "A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Pneumococcal Infections" ], "interventions": [ { "name": "Pneumococcal Vaccine, Polyvalent (23-valent)", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine, Heptavalent", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "6 Months", "sex": "ALL", "summary": "2 Months to 6 Months" }, "enrollment_count": 60, "start_date": null, "completion_date": "1999-10", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 31, "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000829" }, { "nct_id": "NCT00904202", "title": "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postherpetic Neuralgia", "Diabetic Neuropathy", "Complex Regional Pain Syndrome", "Carpal Tunnel Syndrome", "HIV Neuropathy", "Idiopathic Sensory Neuropathy", "Peripheral Neuropathy" ], "interventions": [ { "name": "Placebo Capsules + Placebo Patch", "type": "DRUG" }, { "name": "Placebo capsules + Lidoderm®", "type": "DRUG" }, { "name": "Gabapentin + Placebo", "type": "DRUG" }, { "name": "Gabapentin + Lidoderm®", "type": "DRUG" }, { "name": "Gabapentin 300 mg capsules 1800 mg/day + placebo patch", "type": "DRUG" }, { "name": "Gabapentin 1800 mg/day + Lidoderm patch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2003-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hueytown", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00904202" }, { "nct_id": "NCT02666053", "title": "A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "BMS-663068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2016-01-27", "completion_date": "2016-02-22", "has_results": false, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02666053" }, { "nct_id": "NCT00002051", "title": "Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Thymopentin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunobiology Research Institute", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 1, "location_summary": "Annandale, New Jersey", "locations": [ { "city": "Annandale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002051" }, { "nct_id": "NCT00002302", "title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Cytopenias" ], "interventions": [ { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ortho Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Raritan, New Jersey", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Raritan", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002302" }, { "nct_id": "NCT00000801", "title": "Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Filgrastim", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 33, "start_date": null, "completion_date": "1998-04", "has_results": false, "last_update_posted_date": "2012-11-01", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000801" }, { "nct_id": "NCT01755741", "title": "Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Placebo Vaginal Ring", "type": "COMBINATION_PRODUCT" }, { "name": "Condom", "type": "DEVICE" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DEVICE" ], "sponsor": "International Partnership for Microbicides, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 70, "start_date": "2013-02", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-03T12:31:16.170Z", "location_count": 2, "location_summary": "Berkeley, California • Los Angeles, California", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01755741" } ] }